Rigel enrols first participant in Phase Ib/II AML treatment regimen trial
Rigel Pharmaceuticals has announced the enrolment of the first subject in a Phase Ib/II clinical trial of REZLIDHIA (olutasidenib) in…
Company News
Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases
Boehringer and CDR-Life report data from geographic atrophy treatment trial
Lilly’s efsitora shows promise in Phase III type 2 diabetes trials
IN8bio cuts staff and pipeline to focus on AML cell therapy
FDA grants IND clearance for Adaptin Bio’s Phase I glioblastoma therapy trial
WashU Medicine finds anti-clotting drugs fail to improve stroke care outcomes
Vesper Bio reports data from Phase I frontotemporal dementia treatment trial
